Balaxi Pharmaceuticals Ltd
BALAXIBalaxi Pharmaceuticals Ltd
BALAXI
Price Chart
Scorecard
Performance
LowHasn't fared well - amongst the low performers
Valuation
HighSeems to be overvalued vs the market average
Growth
LowLagging behind the market in financials growth
Profitability
AvgAverage profitability - not good, not bad
Entry point
GoodThe stock is underpriced and is not in the overbought zone
Red flags
LowNo red flag found
How to use scorecard? Learn more
Key Metrics
| No LabelNo Label | PB RatioPB Ratio | Dividend YieldDiv. Yield |
|---|---|---|
| 11.65 | 2.06 | — |
| Sector PESector PE | Sector PBSector PB | Sector Div YldSctr Div Yld |
|---|---|---|
| 51.23 | 6.64 | 0.52% |
Forecast & Ratings
Detailed Forecast Price
Price Upside
Earnings
Earnings Growth
Revenue
Rev. Growth
Company Profile
The company is engaged in wholesale trading of pharmaceuticals products, food products and builders’ hardware products. The Company offers a range of food and biscuit products under the brand name YAP.
Investor Presentation
View olderPeers
Compare with peersInventurus Knowledge Solutions Ltd
Poly Medicure Ltd
Tarsons Products Ltd
Borosil Scientific Ltd
PREVEST DENPRO LTD
Get more out of Tickertape, Go Pro!
Customise key metrics, see detailed forecasts, download stock data and more
Forecasts
Price
Revenue
Earnings
Price Forecast
Hmm, looks like data is unavailable here. Please come back after some timeRevenue Forecast
Hmm, looks like data is unavailable here. Please come back after some timeEarnings Per Share Forecast
Hmm, looks like data is unavailable here. Please come back after some timeIncome
Balance Sheet
Cash Flow
Income Statement
| Financial Year | FY 2019 | FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | TTM | |||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | 14.49 | 46.22 | 233.56 | 284.36 | 339.07 | 241.92 | 258.47 | |||||||
Raw Materials | 0.00 | 32.83 | 172.15 | 195.60 | 202.42 | 128.68 | 215.83 | |||||||
| Power & Fuel Cost | 0.00 | 0.00 | 0.00 | 0.35 | 0.28 | 0.04 | ||||||||
| Employee Cost | 0.90 | 2.10 | 8.47 | 12.47 | 28.95 | 28.04 | ||||||||
| Selling & Administrative Expenses | 0.59 | 1.75 | 4.74 | 17.56 | 42.29 | 36.02 | ||||||||
| Operating & Other expenses | 10.55 | 0.70 | 3.30 | 2.59 | 5.08 | 42.27 | ||||||||
EBITDA | 2.45 | 8.84 | 44.90 | 55.79 | 60.05 | 6.87 | 42.64 | |||||||
| Depreciation/Amortization | 0.00 | 0.01 | 0.30 | 0.51 | 1.75 | 2.10 | 2.10 | |||||||
| PBIT | 2.45 | 8.83 | 44.60 | 55.28 | 58.30 | 4.77 | 40.54 | |||||||
| Interest & Other Items | 0.00 | 0.05 | 0.28 | 0.76 | 1.38 | 2.77 | 1.84 | |||||||
| PBT | 2.45 | 8.78 | 44.32 | 54.52 | 56.92 | 2.00 | 38.70 | |||||||
| Taxes & Other Items | 0.47 | 2.69 | 6.19 | 6.86 | 10.96 | 4.40 | 3.10 | |||||||
| Net Income | 1.98 | 6.09 | 38.13 | 47.66 | 45.96 | -2.40 | 35.60 | |||||||
| EPS | 1.30 | 1.87 | 7.63 | 9.53 | 9.11 | -0.46 | 6.53 | |||||||
| DPS | 0.00 | 0.00 | 0.00 | 0.10 | 0.00 | 0.00 | 0.00 | |||||||
| Payout ratio | 0.00 | 0.00 | 0.00 | 0.01 | 0.00 | 0.00 | 0.00 |
Company Updates
Investor Presentation
Investor Presentation
Investor Presentation
Investor Presentation
Peers & Comparison
Health CareHealth Care Equipment & Supplies
Valuation
Technical
Forecast
Compare valuation on Screener| Stock | PE RatioPE Ratio | PB RatioPB Ratio | Div. YieldDividend Yield |
|---|---|---|---|
| Balaxi Pharmaceuticals Ltd | -172.83 | 2.06 | — |
| Inventurus Knowledge Solutions Ltd | 86.55 | 27.69 | 0.53% |
| Poly Medicure Ltd | 99.33 | 17.45 | 0.11% |
| Tarsons Products Ltd | 48.98 | 3.41 | 0.51% |
Price Comparison
Compare BALAXI with any stock or ETFShareholdings
Promoter Holdings Trend
Total Promoter Holding
In last 6 months, promoter holding in the company has almost stayed constant
Low Pledged Promoter Holding
Pledged promoter holdings is insignificant
Institutional Holdings Trend
Total Retail Holding
In last 3 months, retail holding in the company has almost stayed constant
Foreign Institutional Holding
In last 3 months, foreign institutional holding of the company has almost stayed constant
Shareholding Pattern
Mar 2024
Apr 2024
Jun 2024
Sep 2024
Shareholding History
Hmm, looks like there hasn't been any net deal activity in the last 6 monthssmallcases
Looks like this stock is not in any smallcase yet.
Events
Dividend Trend
No dividend trend available
Dividends
Corp. Actions
Announcements
Legal Orders
Upcoming Dividends
No upcoming dividends are available
Past Dividends
Cash Dividend
Ex DateEx DateJul 1, 2022
Dividend/Share
₹0.50
Ex DateEx Date
Jul 1, 2022
Net profit of Balaxi Pharmaceuticals declined 68.19% to Rs 4.59 crore in the quarter ended September 2024 as against Rs 14.43 crore during the previous quarter ended September 2023. Sales rose 41.41% to Rs 77.38 crore in the quarter ended September 2024 as against Rs 54.72 crore during the previous quarter ended September 2023. ParticularsQuarter EndedSep. 2024Sep. 2023% Var. Sales77.3854.72 41 OPM %13.6919.66 - PBDT6.0310.67 -43 PBT5.5610.01 -44 NP4.5914.43 -68 Powered by Capital Market - Live
Balaxi Pharmaceuticals will hold a meeting of the Board of Directors of the Company on 5 November 2024Powered by Capital Market - Live
Net profit of Balaxi Pharmaceuticals reported to Rs 6.48 crore in the quarter ended June 2024 as against net loss of Rs 41.34 crore during the previous quarter ended June 2023. Sales declined 0.52% to Rs 65.62 crore in the quarter ended June 2024 as against Rs 65.96 crore during the previous quarter ended June 2023. ParticularsQuarter EndedJun. 2024Jun. 2023% Var. Sales65.6265.96 -1 OPM %15.3813.40 - PBDT7.877.54 4 PBT7.377.26 2 NP6.48-41.34 LP Powered by Capital Market - Live
Balaxi Pharmaceuticals announced that the 81st Annual General Meeting(AGM) of the company will be held on 23 August 2024.Powered by Capital Market - Live
Balaxi Pharmaceuticals will hold a meeting of the Board of Directors of the Company on 2 August 2024.Powered by Capital Market - Live
Higher than Industry Revenue Growth
Over the last 5 years, revenue has grown at a yearly rate of 75.6%, vs industry avg of 16.6%
Increasing Market Share
Over the last 5 years, market share increased from 1.21% to 4.74%